Compare BioNano Genomics Inc (BNGO) vs Lowe`s Companies Inc (LOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Lowe`s Companies Inc — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.66M), while Lowe`s Companies Inc trades at $215.3 (market cap $124.06B). The key difference: Lowe`s Companies Inc is far larger — about 9082× BioNano Genomics Inc's market cap, and Lowe`s Companies Inc pays a 2.26% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | LOW | |
|---|---|---|
Market Cap | $13.66M | $124.06B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $287.39 |
52-Week Low | $1.06 | $201.92 |
Enterprise Value | $16.26M | $165.81B |
Dividend Yield | — | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
Lowe's (LOW) trades at $218.84, down 2.02% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company has beaten earnings estimates for the last three quarters, with Q2 2026 results expected on August 19. Revenue declined to $83.67 billion in 2025, but net income margin remained healthy at 7.51%. A $1.25 dividend is scheduled for payment on August 5, 2026.
The outlook is supported by strong analyst consensus, with a $257.06 price target implying 17% upside. Risks include high debt levels and competitive pressures. Earnings growth in the professional segment is a key catalyst, but macroeconomic headwinds could challenge DIY sales momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →
